All Activity

I’m encouraged while using surpassing along with preachy list that you just adorn such minor timing. Google Ads Agency London

this can be awesome plus meanful. this can be interesting site. Leading is rather handy element. you may have seriously made it simpler for many people who seem to take a look at site and give these folks usefull information and facts. Google Ads Agency London

This is my first time i visit here and I found so many interesting stuff in your blog especially it's discussion, thank you. 도파민가라오케

Document went on your web page at the same time re-focusing only just to some extent submits. Excellent technique for so next, I'll be book-marking instantly catch any carry out springs up. 구구단쩜오

Cheap content, With thanks just for stating This approach skills. Wonderfully developed page, only if all of the the blogosphere obtainable the equivalent degree content and articles simply because, websites became a more desirable space. Delight continue! 구구단쩜오

Marijuana regulators in Washington say that the Trump administration’s move to reschedule cannabis on the federal level “does not appear to apply” to businesses in the state. The U.S. Department of Justice in April issued an order that immediately reclassified state-licensed medical cannabis, as well as marijuana products approved by the Food and Drug Administration (FDA) from Schedule I of the Controlled Substances Act (CSA) to Schedule III. A hearing scheduled for later this month will consider more comprehensively moving marijuana to Schedule III. “Washington does not license medical cannabis producers, processors, or retailers,” the state Liquor and Cannabis Board (LCB) said in guidance published on Tuesday. “Instead, Washington has a single recreational market and within that market producers/processors may manufacture [Department of Health]-compliant products, and certain retailers may sell DOH-compliant products to all adult patients and designated providers.” “Because of this, Washington’s cannabis licensees do not appear to qualify as ‘state medical marijuana licensee[s]’ and therefore may not be eligible to register under the Final Rule,” the agency said, referring to a Drug Enforcement Administration (DEA) registration process for state-legal marijuana businesses to take advantage of federal benefits that come with the reform. That said, LCB is “not taking a position to prevent licensees from applying for federal registration if they choose,” the guidance continues. “If any licensee does apply for federal registration, we would be interested in learning about their experience and any federal determination.” Nonetheless, “based on our analysis, federal rescheduling in its current form does not appear to apply to Washington’s cannabis licensees due to the statutory framework predominately regulating recreational cannabis,” LCB said. The agency did stress, however, that while it has consulted with the Cannabis Regulators Association, National Governors Association and industry stakeholders, its current view does not represent the formal opinion of Washington and “may not be our final interpretation as information is evolving and the determination may not rest with the state.” “We expect additional guidance from involved federal agencies, new or updated federal agency processes, and/or other federal proceedings,” it said, citing the upcoming administrative hearing and ongoing litigation challenging cannabis rescheduling. “The LCB recognizes there are many cannabis producers, processors, and retailers that actively engage in the production and sales of medical cannabis in Washington. These businesses may or may not have an opportunity to use the 280e tax deduction and additionally register with the DEA for a schedule III permit. The determination of the applicability of 280e and qualification for DEA schedule III permits is with the federal government and not with the state of Washington. It is possible that the state of Washington will ultimately not have any input into the determination as to whether its licensees meet the criteria for ‘state medical marijuana licensees,’ as DOJ may make that determination unilaterally. DOJ has the authority to reasonably interpret the meaning of the Final Rule, and a determination that Washington cannabis licensees do qualify as ‘state medical marijuana licensee[s].'” The U.S. Department of the Treasury and Internal Revenue Service (IRS) said they plan to issue new tax guidance for the marijuana industry following rescheduling. The reform will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions they’re currently barred from under an IRS code known as 280E that doesn’t apply to Schedule III substances. In California, regulators recently adopted emergency rules changes for the state’s marijuana licensing process that are intended to make it easier for businesses to qualify for benefits in line with the Trump administration’s recent move to federally reschedule medical cannabis. The post Federal Marijuana Rescheduling ‘Does Not Appear To Apply’ To Washington Businesses, State Officials Say appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Bipartisan North Carolina lawmakers are stepping up the push for psychedelics reform legislation by asking colleagues to pass it as part of the budget. Several members of the Senate and House of Representatives spoke at a press conference on Tuesday in support of a bill to fund research on the therapeutic value of substances like psilocybin, ibogaine and MDMA in treating military veterans, first responders, frontline healthcare personnel and survivors of domestic violence or sexual assault. “This bill makes a real investment in mental health innovation, research and access to the people of our state,” Sen. Robert Brinson (R), lead sponsor of the Healing through Evidence-based Access to Lifesaving Care (HEAL) Act, said, noting that “momentum is building” for psychedelics reform at the federal and state levels. Rep. Allen Chesser (R) cited statistics about the large number of military veterans who die from suicide, saying that “if we keep doing what we’ve done, we’re going to keep losing the veterans that we’ve sworn to protect.” “This is not a radical liberal idea, and it does not belong to one party or the other,” he said of psychedelics reform. “We stand here, representatives from both sides of the aisle, from both chambers, working together, because good policy crosses borders.” “We’re here today because there is a new option… They’ve had phenomenal results,” Chesser said of psychedelics. “These aren’t fringe ideas. They are on the path to becoming approved medicines.” Sen. Sophia Chitlik (D) said that “study after study…have shown that psychedelics can yield durable, measurable results for treating trauma and depression.” “Veterans give everything to defend our country, and some of the most severe wounds that they come back with are invisible to most of us, but they are not invisible to their loved ones,” she said. “Today I’m proud to say that these wounds are no longer invisible to their legislators.” Chitlik and other lawmakers filed a separate bill last year to authorize the creation of a new state psychedelics task force to study and issue recommendations on providing access to the alternative therapies to address serious mental health conditions. In 2023, a North Carolina House committee approved a separate bill to create a $5 million grant program to support research into the therapeutic potential of psilocybin and MDMA and to create a Breakthrough Therapies Research Advisory Board to oversee the effort. The measure was not ultimately enacted, however. Rep. Eric Ager (D) said that PTSD “is rampant across the veteran community.” “Clearly, what we’re currently doing isn’t working. It’s time to take a close look at the alternatives,” he said. “This bill is the very beginning of that, and I look forward to working with my colleagues. I really hope we get it into the budget and can get it passed.” If the legislation is enacted, a new Breakthrough Therapies Research Grant Fund would be established under the Department of Health and Human Services to award competitive grants for research on drugs designated as “breakthrough therapies” by the federal Food and Drug Administration (FDA). The money would support three-year studies on the benefits of psychedelics for populations that are disproportionately impacted by trauma, with the legislation specifying that “the research study involving psilocybin shall be concentrated on the treatment of anxiety disorder, depressive disorder, or both.” S1018 would also create a new Breakthrough Therapies Task Force charged with studying psychedelics’ potential and barriers to access, reviewing research grant applications and recommending licensing and insurance requirements for therapeutic use. The body would additional be charged with considering “legal and regulatory pathways to the legalization of psychedelic medicines in the State and the potential effects of the medicines on public health.” The legislation, which cites a psychedelics executive order that President Donald Trump signed in April, seeks to appropriate $5.4 million in funding to support the research grants and overall effort. Brinson, the lead sponsor, said at a separate event last year that North Carolina has opportunity to “lead the nation” in expanding access to psychedelic medicine for military veterans suffering from major mental health conditions. Advocates called on lawmakers to pass the legislation. “At a time when so many individuals and families are struggling with mental health challenges that traditional treatments have failed to address, we believe it is crucial to expand access to therapies that are showing promise,” Gina Giorgio, founder of Carolinas for Care, said in a press release. “Our work brings together lived experience, clinical expertise, and community advocacy to ensure that care is informed by science and delivered with compassion.” Logan Davidson, legislative director for Veterans Exploring Treatment Solutions (VETS), said that “veterans across the Carolinas deserve access to treatments that actually work.” “VETS has seen firsthand how psychedelic-assisted therapies can restore what PTSD and traumatic brain injury have taken from those who served—but too many of our veterans are still waiting,” he said. “The HEAL Act gives North Carolina the tools to accelerate the research that can change that, and we’re proud to stand with Carolinas for Care in making that case to the General Assembly.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, North Carolina’s Senate president pro tempore recently said that lawmakers will take a more serious look at legalizing medical marijuana following the Trump administration’s move to reschedule cannabis at the federal level. The North Carolina Senate has passed medical cannabis bills in a number of past sessions that have later stalled out in the House of Representatives. The Senate leader’s comments came weeks after a governor-appointed cannabis commission in North Carolina issued a report recommending that the state move away from a criminalization-based approach to the plant and toward a system of “robust” regulations that provide for adults’ legal access to THC products. The North Carolina Advisory Council on Cannabis, which Gov. Josh Stein (D) convened last year, says in the new document approved in April that the current “absence of regulation for North Carolina’s intoxicating cannabis market raises numerous concerns,” noting that hemp products are readily available yet largely unregulated and that marijuana remains prohibited altogether in the state, even for medical use. Stein, for his part, thanked the group for its “expertise, hard work, and thoughtful deliberation” in a press release and reiterated his support for legalizing marijuana. “Last year, I charged this group with developing a comprehensive solution to the unregulated sale of cannabis that is grounded in public health and public safety, with a special focus on keeping young people safe,” the governor said. “This report provides the General Assembly with guidance and makes clear that a well-regulated market, including both oversight and enforcement authority, is a safer market for our state.” The interim report recommends that rather than construct separate frameworks for hemp and marijuana, the state should enact molecule-based regulation focused on THC itself, saying that “the plant source is irrelevant and should not drive different treatment when the intoxicating compound is the same.” It also suggests that when choosing how to regulate THC and cannabis, North Carolina should enact “an adult access market with protections for medical consumers.” The panel, however, “does not view a medical-only program as an effective interim step or compromise solution,” and the state should proceed to adult-use access immediately while considering the “availability of medical-consumer protections” as “an important component of a broader regulatory structure.” During his time as the state’s attorney general, Stein led a separate task force under then-Gov. Roy Cooper (D) that examined racial injustice issues and ultimately recommended decriminalizing marijuana and studying broader legalization in response to racially disparate enforcement trends. Meanwhile, a tribe in North Carolina, the Eastern Band of Cherokee Indians, launched the state’s first marijuana dispensary in 2024—despite the protests of certain Republican congressional lawmakers. Lawmakers have also filed legislation this session to allow North Carolina voters to decide whether to legalize marijuana for personal or medical use at the ballot box this November. Photo courtesy of Mark Groeneveld. The post Bipartisan North Carolina Lawmakers Say Psychedelic Research Bill Can Help Military Veterans appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Virginia’s governor and key lawmakers have announced the details of a plan to legalize recreational marijuana sales through budget legislation this month following the veto of a previous proposal to enact the reform. Gov. Abigail Spanberger (D) on Tuesday appeared at a press conference alongside legislators who sponsored bills she rejected earlier this year to unveil a new compromise approach that they have agreed on. “We have agreed to a proposal that will create a safe, legal and well-regulated cannabis marketplace here in the commonwealth of Virginia—with recreational sales beginning on July 1, 2027,” the governor said. “We will do it in a way that protects consumers, tamps down with the goal of eliminating the illicit market with clear enforcement and regulatory authority and creates a more competitive market for small businesses and farmers.” “This is what good governing and collaboration looks like—bringing people together, listening carefully and focusing on solutions that are practical, enforceable and in the best interest of Virginians,” she said. “In the end, we all wanted to deliver a marketplace that the commonwealth could implement effectively for the long-term. We have always had this same end goal—an end goal that has been years in the making—so I am proud to stand alongside these dedicated legislators and to be working alongside alongside them to deliver a marketplace built to last.” Sen. Lashrecse Aird (D), the lead sponsor of the Senate version of the previous cannabis measure Spanberger vetoed, said she believes the newly negotiated deal “strikes the right balance.” “Virginians deserve to know that they are buying items that are accurately labeled, properly tested and sold in a secure environment,” she said. “This framework gives us a real path to move demand out of the illicit market and into a regulated system built around safety, accountability and consumer protection.” Del. Paul Krizek (D), who sponsored the House of Delegates version of the earlier marijuana legislation, said the goal is to “create a cannabis market that is responsible” and that gives small businesses “a real chance to succeed.” “For decades, cannabis enforcement created real consequences for individuals, families and documented disproportionate impact to communities,” he said. “A legal marketplace should not lock those same communities out of the economic opportunity created by reform.” “Part of the responsible legalization that we have before you today is recognizing that those past cannabis policies did not affect every community equally as we move into a legal marketplace,” Krizek said. “We have an obligation to make sure opportunity is not limited only to those who already have access to capital and political connections.” The new plan differs significantly in several ways from the earlier legislation that lawmakers passed earlier this year and that the governor vetoed. For example, it sets the launch date for recreational marijuana sales at July 1, 2027, which is what Spanberger proposed in contrast to the January 1 date in what lawmakers had passed. It also sets the legal public marijuana possession and per-transaction purchase limit at 2 ounces, an increase from the current legal limit of one ounce. The legislation lawmakers passed earlier this year would have allowed adults to possess up to 2.5 ounces. The bill also cedes to Spanberger on language to increase a marijuana excise tax from 6 percent to 8 percent after two years of legal sales. By way of compromise, the new agreement would make public consumption of marijuana punishable by a civil penalty of $250—a significant increase from the $25 in current law but less harsh than the class 4 criminal misdemeanor the governor sought in her proposed changes to the previous bill. The penalty increase would not take effect until July 1 of next year, however, raising the possibility that lawmakers could pass legislation next session to rescind it. Lawmakers passed the initial cannabis sales bills in March, but the governor then suggested changes to the legalization proposal—including delaying the start date for sales by six months, increasing taxes and instituting new criminal penalties for cannabis consumers. The legislature in April declined to take up the amendments during a one-day reconvened session, however, effectively rejecting them. Spanberger then issued a veto. Spanberger said last week that she was having “really productive” and “incredible” conversations with lawmakers about crafting a compromise approach to legalizing adult-use cannabis sales, and Marijuana Moment previously reported on the ongoing talks. Following Spanberger’s veto, top lawmakers have been openly discussing the possibility of including provisions to legalize adult-use cannabis sales in still-outstanding budget legislation that they are due to pass by July 1. The effort to keep the issue alive was a topic of discussion at the first meeting of the legislature’s Joint Commission to Oversee the Transition of the Commonwealth into a Cannabis Retail Market since the governor’s move to kill the previous proposal to regulate adult-use marijuana sales. The governor, meanwhile, has tried publicly explain her veto—including by saying it is her view that “taking a little bit longer” to launch the market is not something she sees as “negative” because it is more important to get the details right than to do it fast. A recent survey found that bipartisan majorities of Virginia voters wanted Spanberger to sign the cannabis legislation into law, and that they specifically disagreed with her desire to slow the launch timeline for legal sales. The governor recently acknowledged in a separate interview that “a lot of people are not pleased” with her veto of the cannabis legislation. “Friends and family are displeased as well,” she said. Spanberger has repeatedly responded to criticism of her cannabis amendments from the bill sponsors and advocates by saying the suggested changes came after she spoke to the leaders of other states that have already implemented adult-use marijuana markets. A spokesperson for Spanberger declined to name any other governors she talked to about cannabis in response to a question from Marijuana Moment, however. The governor separately recently sought to explain her veto in an earlier interview, reiterating that she supports launching a legal cannabis market but worried about what she called a “rushed timeline” and “far more stores across Virginia” than she thinks are appropriate. Prior to vetoing the cannabis commerce bill, the governor did sign separate legislation to provide resentencing relief for people with past cannabis convictions. I am excited to announce a compromise proposal for a safe, legal, and well-regulated cannabis marketplace here in Virginia. We will do it in a way that protects consumers, tamps down on the illicit market with clear enforcement and regulatory authority, and keep our kids safe… — Governor Abigail Spanberger (@GovernorVA) June 16, 2026 Personal marijuana possession and home cultivation of marijuana has been legal in Virginia since 2021, but then-Gov. Glenn Youngkin (R) twice vetoed bills to provide consumers with a way to legally purchase regulated adult-use cannabis. Aird and Krizek, the sponsors of the legalization bills, had urged colleagues to vote against the governor’s amendments—even if that meant risking a veto from Spanberger when the legislation returned to her desk. Here are the key details of the new cannabis plan and how it compares to legislation that Spanberger vetoed—SB 542 and HB 642—as well as her previously proposed amendments to those measures: Adults would be able to purchase up to 2 ounces of marijuana in a single transaction, or up to an equivalent amount of other cannabis products as determined by regulators. That would represent an increase from the limit in current law of 1 ounce. Lawmakers previously proposed setting the amount at 2.5 ounces and the governor only wanted 2 ounces. Legal sales could begin on July 1, 2027. Lawmakers previously set the date for January 1, 2027, but the governor wanted it pushed back to July 1. There would be an excise tax of 6 percent on cannabis sales as well as a 5.3 percent retail sales and use tax, and municipalities would be allowed to set an additional local tax of up to 3.5 percent. Starting on July 1, 2029, the state excise tax would increase to 8 percent, in line with the governor’s previously proposed amendments. Revenue would be distributed to the Cannabis Equity Reinvestment Fund, early childhood education, the Department of Behavioral & Developmental Health Services and public health initiatives. The earlier measure passed by lawmakers would have allocated specific percentages to each, but the new language doesn’t specify what portion of revenue will go to each program. The governor, in her amendments, wanted to put all revenue into the general fund while earmarking it “for purposes such as early childhood education, behavioral health, public health awareness, prevention, treatment, and recovery services, workforce development, reentry, indigent criminal defense, and targeted reinvestment in historically disadvantaged communities.” Her amendment also sought to eliminate support for the Cannabis Equity Reinvestment Fund. The Virginia Cannabis Control Authority would oversee licensing and regulation of the new industry, and will also take on oversight of hemp, which is currently under the Department of Agriculture and Consumer Services. The body would be governed by a five-member board of directors appointed by the governor, whereas the bill previously passed by lawmakers contemplated a seven-member body with four appointed by the governor, two appointed by the speaker of the House and one appointed by the Senate Rules Committee. The definition of what constitutes a legal hemp product would be narrowed by removing a provision from current law that allows those containing more than 2 milligrams of total THC per package if they also have a ratio of CBD to THC that is 25:1 or more. Up to 350 retail marijuana stores would be allowed to be licensed to operate across the state, the same number that lawmakers had approved and greater than the 200 the governor had proposed. Local governments would not be able to out of allowing marijuana businesses to operate in their area. Delivery services would be allowed. Serving sizes would be capped at 10 milligrams THC, with no more than 100 mg THC per package. Public use of marijuana would be a civil violation punishable by a $250 fine. That is ten times more than the $25 fine under current law, but less harsh than than the class 4 criminal misdemeanor crime the governor had proposed. Possession of cannabis by people under the age of 21 would be punishable by a $25 fine and mandatory participation in a substance abuse treatment or education program or both. The governor had suggested treating underage possession as a class 1 misdemeanor, punishable with a mandatory minimum fine of $500 or 50 hours of community service, as well as the suspension of drivers licenses for at least six months. Existing medical cannabis operators could enter the adult-use market if they pay a $10 million licensing conversion fee. Cannabis businesses would have to establish labor peace agreements with workers. A legislative commission would be directed to study adding on-site consumption licenses and microbusiness cannabis event permits that would allow licensees to conduct sales at venues like farmers markets or pop-up locations. That provision was also included in the earlier legislation lawmakers passed but was suggested for deletion by the governor. Marijuana reform advocates cheered the fact that a legal sales deal is coming together, but they expressed concerns about some of the penalty increases in the bill. “This compromise represents a meaningful step toward bringing Virginia’s cannabis laws in line with public opinion and moving the commonwealth closer to a marketplace that consumers have long demanded,” JM Pedini, development director for the advocacy group NORML and executive director for Virginia NORML, said. “Although NORML has deep concerns about provisions in the bill to increase the civil penalty for public cannabis consumption, we are encouraged by other areas of broader agreement. This bill establishes a consumer-friendly regulated marketplace, improves public safety and provides clear rules for everyone involved.” Meanwhile, the governor signed several other reform bills this session—including measures to protect the parental rights of marijuana consumers and allow patients to access medical cannabis in hospitals. The post Virginia Governor And Lawmakers Unveil Newly Negotiated Bill To Legalize Marijuana Sales That’s Expected To Pass This Month appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Thanks for the blog loaded with so many information. Stopping by your blog helped me to get what I was looking for. data keluaran sgp

I would like to say that this blog really convinced me to do it! Thanks, very good post. pengeluaran togel singapura terbaru

Congressional researchers are noting that the Food and Drug Administration (FDA) has missed a legal deadline to publish a list of known cannabinoids as federal hemp laws are set to change later this year in a way that stakeholders argue will upend the existing market. As part of appropriations legislation that President Donald Trump signed last year, many hemp products that were legalized during his first term in office under the 2018 Farm Bill will be prohibited once again starting in November. The spending measure included separate provisions, however, directing FDA and other relevant agencies to study the cannabinoid marketplace and develop lists of cannabis components. After the bill was signed, FDA was given 90 days to publish 1) a list of “all cannabinoids known to FDA to be capable of being naturally produced” by cannabis 2) a list of “all tetrahydrocannabinol class cannabinoids known to the agency to be naturally occurring in the plant” and 3) a list of “all other know cannabinoids with similar effects to, or marketed to have similar effects to, tetrahyrocannabinol class cannabinoids.” Further, the agency was tasked with providing “additional information and specificity about the term ‘container’” with respect to hemp product THC serving sizes. In the bill, the term is defined as “the innermost wrapping, packaging, or vessel in direct contact with a final hemp-derived cannabinoid product in which the final hemp-derived cannabinoid product is enclosed for retail sale to consumers, such as a jar, bottle, bag, box, packet, can, carton, or cartridge.” The lists and information was due months ago, on February 10, but FDA did not follow through by the deadline—and still hasn’t published the required information. Now, the Congressional Research Service (CRS) is noting in a report published late last month that the law “requires FDA to consult with relevant federal agencies and publish [the guidance] within 90 days of enactment (which, as of May 2026, has not been published).” Marijuana Moment sent several requests to FDA for an update on its plans to publish the required guidance and any reaction to CRS’s report, but representatives did not reply. A spokesperson for the U.S. Department of Health and Human Services (HHS), of which FDA is a component, told Marijuana Moment earlier this year that it was the agency’s intention to provide the lists in time and that they would be published in the Federal Register. However, that’s yet to materialize—and officials did not provide clarification when asked for an update. Hemp derivatives with less than 0.3 percent delta-9 THC on a dry-weight basis were federally legalized under the 2018 Farm Bill that Trump signed during his first term in office. But late last year, the president signed new spending legislation containing provisions that will redefine hemp to make it so only products with 0.4 milligrams of total THC per container will remain legal after November 12. Lawmakers from both parties have filed several bills and amendments to delay, alter or cancel the planned recriminalization of hemp THC products, but none of those proposals have gained traction with congressional leadership. The new CRS report, meanwhile, said that as the U.S. Department of Agriculture (USDA) reworks hemp regulations in line with the new definition of legal products, “Congress may consider the potential effects on farmers, law enforcement, and consumers.” “For example, Congress may conduct oversight of USDA implementation of the definitional changes in the department’s Domestic Hemp Production Program and the impact of the definitional changes on hemp producers,” it says. The White House this month issued a statement saying the Trump administration wants Congress to take action to amend the law in order to keep hemp-derived full-spectrum CBD products legal. In April, the president himself urged congressional lawmakers to again redefine hemp to avoid recriminalization of full-spectrum CBD products. “I am calling on Congress to update the Law to ensure that Americans can continue to access the full-spectrum CBD products they have come to rely on, and that help them, while preserving Congress’s intent to restrict the sale of products that pose Health risks,” Trump said in a Truth Social post on the same day his administration announced it is moving forward with rescheduling marijuana. “We must get this done RIGHT and FAST, especially for those who saw that CBD helps them,” he said. “Plus, I am told it will also help our GREAT FARMERS, who we love, and will always be there for.” Photo courtesy of Kimzy Nanney. The post Congressional Researchers Call Out FDA For Missing Deadline To Publish Cannabinoid List And Define Hemp ‘Containers’ appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

New congressional bill to keep hemp THC drinks legal; CA GOP senator: Repeal marijuana legalization; Study: Sleep & cannabis about more than THC Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there. Support our work at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The National Institute of Standards and Technology added dozens of marijuana components to an official government library of compounds—providing “reference spectra needed to identify rare plant variants, degradation artifacts and minor homologs that are becoming increasingly relevant in modern cannabis testing.” Rep. Beth Van Duyne (R-TX) is circulating a draft bill that would keep hemp THC beverages federally legal, with new regulations—creating a carve-out from the broad recriminalization of hemp products that is set to take effect in November. A California Republican senator said it’s time to have a “serious discussion” about putting a measure on the ballot to potentially “reverse” marijuana legalization—also raising concerns about President Donald Trump’s move to reschedule cannabis at the federal level. Andrea Efre of the University of South Florida College of Nursing authored a Marijuana Moment op-ed detailing a new study she helped conduct on cannabis and sleep—finding that “the strongest evidence for improving sleep was associated with cannabidiol (CBD), cannabinol (CBN) and combinations of the two—but not primarily THC.” The Rhode Island Senate confirmed a new chair of the Cannabis Control Commission on the last day of the legislative session. / FEDERAL White House Office of National Drug Control Policy Director Sara Carter sent an open letter about what she called the World Anti-Doping Agency’s “unjustifiable exclusion” of the U.S. from an upcoming executive committee meeting. The Drug Enforcement Administration Museum sent a newsletter with various updates. / STATES A Pennsylvania Republican senator called out the Senate minority leader over the defeat of his cannabis regulatory bill, tweeting, “Chinese weed in gas stations is Pennsylvania’s teen cannabis policy. Next kid that dies is on you Jay. You asked for the ‘No vote.'” California regulators are moving to change rules on cannabis plant tagging. Washington State regulators sent a notice about an increase in cannabis license fees taking effect on July 1. Massachusetts’s new top cannabis regulator discussed his priorities in the role. Virginia regulators discussed the implications of federal marijuana rescheduling. Oregon regulators posted a summary of listening sessions about the psilocybin services program. The Nevada Cannabis Compliance Board will meet on Thursday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL The mayor of Forest Lake, Minnesota opened a marijuana dispensary. / INTERNATIONAL Ontario, Canada officials ordered SNDL Inc. to sell its network of several dozen cannabis stores in the province or risk having its licenses revoked. / SCIENCE & HEALTH A study of patients with spinal cord injury found that “CBD significantly reduced the self-reported intensity of neuropathic pain and was generally well-tolerated.” A study of rats found that “CBD may support opioid-sparing pain management strategies.” / ADVOCACY, OPINION & ANALYSIS The Kentucky Democratic Party criticized a Republican lawmaker’s comments about prosecuting people who comply with Gov. Andy Beshear’s (D) executive order to expand medical cannabis access. The Cannabis Regulators Association elected new executive board members. / BUSINESS Vireo Growth Inc. is acquiring C21 Investments Inc. High Tide Inc. is acquiring J. Supply Holdings Inc., operating as Northern Helm. Canopy Growth Corporation reported quarterly net revenue of C$71.2 million and a net loss from continuing operations of C$154.7 million. FLUENT Corp.’s interim CEO stepped down. / CULTURE Former basketball player Shaquille O’Neal said he “never really liked the smell” of marijuana. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Chris Wallis // Side Pocket Images. The post Feds add new cannabis components to research library (Newsletter: June 16, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

This particular is usually apparently essential and moreover outstanding truth along with for sure fair-minded and moreover admittedly useful My business is looking to find in advance designed for this specific useful stuffs… แทงบอลโลก

This is such a great resource that you are providing and you give it away for free. I love seeing blog that understand the value of providing a quality resource for free. แทงบอล

I am impressed. I don't think Ive met anyone who knows as much about this subject as you do. You are truly well informed and very intelligent. You wrote something that people could understand and made the subject intriguing for everyone. Really, great blog you have got here. เว็บแทงบอลออนไลน์

A Republican congresswoman is circulating draft legislation that would keep hemp THC beverages legal under federal law, creating a carve-out from the broad recriminalization of products derived from the crop that is set to take effect later this year, Marijuana Moment has learned. The Hemp-Derived Beverage Regulatory Clarity Act from Rep. Beth Van Duyne (R-TX), in its current form, would allow adults over 21 to purchase and consume hemp THC drinks with up to 5 milligrams of delta-9 THC per serving. It would also impose a federal tax of 10 cents per milligram of any hemp-derived cannabinoid contained within such beverages. Hemp drinks would be regulated by the Treasury Department’s Tax and Trade Bureau (TTB) in consultation with the Department of Health and Human Services, and TTB could set requirements for hemp beverage testing, packaging, labeling and serving and container sizes. Legal beverages could only contain naturally-occurring cannabinoids that are cultivated and processed within the U.S. “A naturally-occurring cannabinoid regulated in accordance with [the bill] shall be deemed safe and may be added to a hemp-derived beverage intended for human consumption,” the draft bill obtained by Marijuana Moment says. Manufactures, distributor, wholesales and sellers of hemp drinks would be required to obtain federal permits. Companies could not sell multi-serving containers larger than 750 milliliters under the legislation. It also directs the National Academies of Science, Engineering, and Medicine to publish a report on the safety of naturally-occurring cannabinoids and their use in beverages, while requiring TTB to issue a separate report on the proper serving sizes for hemp-derived beverages. The legislation further clarifies that states, Indian tribes and localities could set regulations that are “more stringent” than federal rules, but says that they could not prohibit the shipment or transportation of hemp beverages through their borders on the way to other jurisdictions. The draft bill has not yet been formally introduced, and its provisions could change before that happens. Staff for Van Duyne did not respond to Marijuana Moment’s request for comment for this story. Hemp derivatives with less than 0.3 percent delta-9 THC on a dry-weight basis were federally legalized under the 2018 Farm Bill that President Donald Trump signed during his first term in office. But late last year, he signed new legislation containing provisions that will redefine hemp to make it so only products with 0.4 milligrams of total THC per container will remain legal after November 12. The circulation of the new draft legislation comes as the White House is separately making it clear that Trump wants Congress to take action to amend the law that threatens to federally recriminalize hemp-derived products. The administration “welcomes the opportunity to work with the Congress to, at a minimum, update the statutory definition of final hemp-derived cannabinoid products to allow Americans to benefit from access to appropriate full-spectrum CBD products,” the Office of Management and Budget (OMB) said this month, “while preserving the Congress’s intent to restrict the sale of products that pose serious health risks.” The call to avert a broad prohibition on hemp CBD products was included in a statement of administration policy about an annual agriculture spending bill that passed the House of Representatives. Several lawmakers had filed amendments to that legislation to keep hemp products legal, but each was either blocked by the House Rules Committee from advancing to a floor vote or withdrawn by its sponsor. “The Administration supports advancement of this legislation, but looks forward to addressing its concerns prior to enactment,” OMB said in its statement of administration policy. “The Administration looks forward to working with the Congress to provide more input as the bill’s legislative process unfolds.” In April, the president himself urged congressional lawmakers to again redefine hemp to avoid recriminalization of full-spectrum CBD products. “I am calling on Congress to update the Law to ensure that Americans can continue to access the full-spectrum CBD products they have come to rely on, and that help them, while preserving Congress’s intent to restrict the sale of products that pose Health risks,” Trump said in a Truth Social post on the same day his administration announced it is moving forward with rescheduling marijuana. “We must get this done RIGHT and FAST, especially for those who saw that CBD helps them,” he said. “Plus, I am told it will also help our GREAT FARMERS, who we love, and will always be there for.” Industry advocates say that the law as enacted last year not only threatens to prohibit intoxicating and synthetic cannabinoid products but also stands to remove popular full-spectrum CBD products that many Americans use therapeutically from the market. “ONE in FIVE adults used it in the past year, and many say it improved their chronic pain enormously,” the president said in his social media post, adding that hemp-derived CBD “has made a HUGE difference for so many people.” He also referenced a new initiative the administration launched in April to cover up to $500 worth of hemp-derived products each year for eligible Medicare patients. The program being implemented by the Centers for Medicare & Medicaid Services (CMS) focuses largely on CBD but also allows products to have up to 3 milligrams of total THC per serving. “In December, I signed a very important Executive Order calling for Research and Innovation for Hemp-derived CBD,” Trump said. “Our wonderful Dr. Mehmet Oz moved fast to follow the directive in the Executive Order, and launched a model for some Seniors earlier this month. But more must be done!” “Please get it done, and SOON,” the president said in reference to a congressional fix for the broad recriminalization set to take effect in November. “Thank you for your attention to this matter!” It’s not clear how far Trump wants to scale back the scope of the scheduled federal restrictions on hemp products and what kinds of revised THC rules and limitations he would prefer to sign into law. Separately, White House officials recently provided a congressman’s office with feedback on hemp regulatory legislation. In April, Vince Haley, director of the White House Domestic Policy Council and James Braid, assistant to the president for legislative affairs, sent hemp policy suggestions to Rep. Andy Barr (R-KY). “We appreciate your work to advance the policy of” an executive order Trump signed in December that included provisions seeking to protect Americans’ access to CBD products, the staffers wrote in a letter to the congressman. “We are transmitting for your consideration draft legislative text and comments to address the statutory definition of final hemp-derived cannabinoid products in order to allow Americans to benefit from access to appropriate full-spectrum CBD products while preserving the Congress’s intent to restrict the sale of products that pose serious health risks,” the White House officials said, according to a social media post containing a screenshot of the letter. “We are available for discussion and further technical assistance.” Separately, anti-marijuana organizations filed a lawsuit suit against the Medicare hemp CBD coverage policy—but a judge dismissed the case last month, ruling that they don’t have standing. Lawyers for Health and Human Services Sec. Robert F. Kennedy Jr. and CMS Director Mehmet Oz had filed a brief asking that the case be dismissed. The White House Office of Management and Budget has also held a series of meetings about a Food and Drug Administration (FDA) CBD products enforcement policy. FDA issued guidance making clear that it does not intend to interfere with implementation of the Medicare hemp-derived products coverage plan. CMS separately finalized a rule that will allow coverage of some hemp products as specialized, non-primarily health-related benefits through Medicare Advantage plans. As hemp products have become more popular with consumers, some large brands are attempting to get in on action. Major retailer Target, for example, is expanding its participation in the hemp-derived THC beverage market. Last year, the company began a pilot program involving sales of cannabis drinks at 10 select stores in Minnesota. That apparently went well, and now the company has obtained licenses from Minnesota regulators to sell lower-potency hemp edible products—including THC drinks—at all 72 of its stores in the state. A U.S. Department of Agriculture report published in April shows that farmers in the U.S. grew three-quarters of a billion dollars worth of hemp crops in 2025—a 64 percent increase from the prior year. Read the full draft hemp beverage bill below: The post GOP Lawmaker Circulates Bill To Keep Hemp THC Drinks Federally Legal appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“We found that the strongest evidence for improving sleep was associated with cannabidiol (CBD), cannabinol (CBN) and combinations of the two—but not primarily THC.” By Andrea Efre, University of South Florida College of Nursing The cannabis sleep market represents a shift away from traditional pharmaceuticals toward a natural alternative. Historically, cannabis products marketed for sleep have largely focused on THC because of its sedating qualities. Dispensary recommendations, product marketing and consumer assumptions have reinforced the belief that THC is the cannabinoid most responsible for helping people sleep. But our new research, recently published in the Journal of the American Association of Nurse Practitioners, suggests it may be time to rethink that assumption. After conducting a systematic review and meta-analysis of medical cannabis for insomnia, we found that the strongest evidence for improving sleep was associated with cannabidiol (CBD), cannabinol (CBN) and combinations of the two—but not primarily THC. Across the available evidence, medical cannabis was associated with reduced sleep disturbance, increased total sleep time and less daytime sleepiness. Yet THC-containing formulations did not demonstrate significant improvements in sleep outcomes and were associated with higher rates of adverse effects. This finding matters because nearly one in four Americans reports using cannabis to improve sleep, while more than one-third of adults fail to obtain adequate sleep on a regular basis. Faced with insomnia, limited access to behavioral therapies and concerns about conventional sleep medications, millions of consumers are turning to cannabis and often relying on marketing claims, online forums and anecdotal experiences rather than clinical evidence to guide their decisions. To better understand what the science actually shows, we reviewed nearly 4,600 studies and identified 18 that met rigorous inclusion criteria, with seven eligible for meta-analysis. These studies evaluated CBD, CBN, THC and cannabinoid combinations administered as capsules, oils, tinctures and sublingual preparations. Compared with placebo, medical cannabis was associated with meaningful improvements in sleep disturbance, total sleep time and daytime sleepiness. Adverse effects were generally mild to moderate and most commonly included drowsiness, dry mouth, dizziness and gastrointestinal symptoms. CBD and CBN consistently demonstrated the most promising results. CBD doses ranging from 50 to 300 milligrams and CBN doses ranging from 20 to 100 milligrams were associated with the most consistent improvements in sleep quality and duration. Lower-dose CBD products, particularly those containing less than 50 milligrams, generally showed little benefit unless combined with CBN. This finding raises an uncomfortable question for the rapidly expanding sleep-products marketplace. Many commercially available CBD sleep products contain doses substantially lower than those evaluated in clinical studies. Consumers may assume that because a product contains CBD and is marketed for sleep, it reflects the available evidence. In many cases, that assumption may be wrong. THC performed differently. Despite its reputation as the cannabinoid most associated with sleep, THC-containing formulations produced mixed results and were associated with higher rates of adverse effects, while CBD- and CBN-focused formulations demonstrated more consistent benefits across studies. This does not mean THC has no role in sleep management, but it does suggest that its reputation as the primary sleep-promoting cannabinoid may be stronger than the evidence supporting it. For decades, the public conversation surrounding cannabis and sleep has focused primarily on THC. Meanwhile, CBD and CBN—two cannabinoids that showed greater promise in the available evidence—have received comparatively less attention. If clinicians, researchers, manufacturers and consumers are genuinely interested in improving sleep outcomes, future conversations should be driven by evidence rather than assumptions. The evidence suggests cannabinoids are generally well tolerated when appropriately dosed and monitored, but informed use still matters. Like many therapeutic agents, cannabinoids can interact with prescription medications and potentially alter drug concentrations. People taking blood thinners, cardiovascular medications, psychiatric medications or multiple prescription drugs should talk with their healthcare provider about potential interactions before adding cannabinoid products to their routine. More research is needed, particularly larger and longer-term clinical trials using standardized formulations and dosing protocols. Yet the evidence is already strong enough to challenge one of the most common assumptions in cannabis medicine. For years, consumers have been told that THC is the cannabinoid most closely linked to sleep. Our review suggests the science is telling a different story. If the goal is truly evidence-based cannabis medicine, the future of sleep therapy may depend not on asking whether cannabis works, but on identifying which cannabinoids work best. Dr. Andrea Efre is an associate professor at the University of South Florida College of Nursing and a nurse practitioner with over a decade of experience speaking to nurses and healthcare professionals about cannabis. She and her colleagues recently completed a systematic review and meta-analysis examining the impact of medical cannabis on insomnia. From their work they developed a clinical resource for healthcare providers and are sharing their work throughout health communities. The post Our New Study Shows That The Science Of Cannabis And Sleep Extends Beyond THC (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A California Republican senator says it is time to have a “serious discussion” about putting a measure on the ballot to potentially “reverse” legalization of marijuana in the state—also raising concerns about President Donald Trump’s move to reschedule cannabis at the federal level. “I think it’s time to assess the effects, the significant unintended consequences of the legalization of marijuana, which has not just happened in California, but in other states too,” Sen. Roger Niello (R) said at a hearing of the Senate Business, Professions and Economic Development Committee last week. “Now we can’t change it without going back to the people, but I think we should have a serious discussion, a serious analysis of the obvious…unintended negative consequences I don’t think that the writers of the proposition cared about,” he said as first reported by State Affairs, referring to the cannabis legalization ballot initiative that California voters approved in 2016. “I think these could have been predicted. They just wanted recreational use to be legalized.” Niello raised concerns that “we’re even seeing our current president now advocating that by downplaying the classification of marijuana at the federal level.” “We have seen significant negative consequences of this legalization, both here as well as in other states,” the senator, who was speaking at a hearing at which lawmakers approved a bill to legalize marijuana dispensary drive-thru windows in California, said. “I think it’s time for us to have a serious analysis of that, and whether or not we want to develop a proposition to go back to the voters and either reverse it or somehow reform it so that we don’t continually deal with the problems that we do.” “I oppose the legalization of marijuana,” he said, citing data about cannabis use by young people and an alleged link to mental health problems and claiming that the 2016 reform was “written to please everybody” which resulted in a “dysfunctional policy that is bound for unintended consequences.” Elsewhere in the U.S., marijuana legalization opponents are currently collecting signatures to put measures to roll back the reform in Maine and Massachusetts—though those anti-cannabis campaigns have faced accusations of misleading petitioning tactics. A separate anti-marijuana effort in Arizona for a similar measure was dropped after its lead organizer said his initial concerns about the legal cannabis industry were misplaced. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Back in California, regulators recently adopted emergency rules changes for the state’s marijuana licensing process that are intended to make it easier for businesses to qualify for benefits in line with the Trump administration’s recent move to federally reschedule medical cannabis. They also separately launched a new AI tool to help businesses identify marijuana product packaging may appeal to kids in violation of state rules. Gov. Gavin Newsom (D), meanwhile, recently took credit for helping to lead the push for the state to legalize marijuana and discussed his own limited experience with using cannabis. In October, however, Newsom vetoed a bill that would have allowed certain marijuana microbusinesses to ship medical cannabis products directly to patients via common carriers like FedEx and UPS, stating that the proposal “would be burdensome and overly complex to administer.” Newsom did sign a bill earlier that month aimed at streamlining research on marijuana and psychedelics. In September, the governor also signed a measure into law to put a pause on a recently enacted tax hike on marijuana products. Separately, the state attorney general says Indian tribes cannot independently engage in marijuana commerce with licensed cannabis businesses without first obtaining their own commercial license from state officials. California officials recently awarded nearly $30 million in grants for marijuana-focused academic research projects. The post California GOP Senator Suggests Putting Marijuana Back On The Ballot To ‘Reverse’ Legalization appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The new chair of the Cannabis Control Commission had previously led the state’s Cannabis Office. By Christopher Shea, Rhode Island Current The independent state agency shaping the nascent cannabis industry is whole again, with a new chairperson confirmed by the Rhode Island Senate on its final day of the legislative session. The chamber’s unanimous vote Thursday confirms Michelle Reddish as chair of the Cannabis Control Commission, filling the seat left open since October when former leader Kim Ahern resigned to run for attorney general. Reddish, who has led the state’s Cannabis Office since 2024, now transitions from operational duties to policymaking as chair of the commission. The $204,069 post is the only full-time position on the panel charged with regulating the state’s medical and recreational marijuana and hemp industries. Also Thursday, the Senate reappointed commissioner Robert Jacquard for a second term on the cannabis panel. Both Jacquard and Reddish will serve until May 17, 2031. This story was first published by Rhode Island Current. Unrelated content excised by Marijuana Moment. Photo courtesy of Chris Wallis // Side Pocket Images. The post Rhode Island Senate Confirms New Top Marijuana Regulator appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A federal science agency has added dozens of new marijuana components to an official government library of compounds that is used to help identify unknown substances in food, drugs, cosmetics, the environment, body fluids and forensic evidence. The National Institute of Standards and Technology (NIST) announced last week that the cannabis components were being added as part of a broader update to its library of mass spectra measured from hundreds of thousands of compounds, known formally as Standard Reference Database 1A. The minor cannabinoids, NIST said, are “trace chemicals hidden inside the cannabis plant that are being explored for medical uses, including pain relief.” In response to a query from Marijuana Moment, NIST officials specified that 41 new spectra related to cannabinoid compounds have been added in this update on top of the 80 that were already included in the library. “By introducing 41 new cannabinoid compounds to the NIST26 library—bringing the total to 121—this expanded collection continues to reflect a strategic selection of compounds that are of significant importance to numerous fields including forensics, biomedical research, food science and environmental chemistry,” NIST data scientist Tytus Mak, who selects the compounds that are added to the database, told Marijuana Moment. To build out the NIST Mass Spectral Library, scientists use a mass spectrometer to effectively generate chemical fingerprints for compounds. The device “ionizes and shatters a compound into charged fragments and then sorts those fragments by their mass-to-charge ratio,” the agency said. When researchers or product manufacturers find a compound of unknown identity, they can us their own mass spectrometry device and then compare the results to NIST’s library to find a match. “Just as a person may be identified by comparing their DNA to a database, a chemical compound may be identified by comparing its mass spectrum to the NIST database,” Bill Wallace, group leader of NIST’s Mass Spectrometry Data Center, said. Who you gonna call when you’re spooked by a mystery compound? NIST! NIST has updated its comprehensive list of chemical fingerprints, called mass spectra, that others rely on to identify unknown compounds in food, drugs, and even space rocks. https://t.co/9J0TJUj4yc pic.twitter.com/UzK7kXAJ3E — National Institute of Standards and Technology (@NIST) June 9, 2026 With respect to the new cannabis-related additions, a summary provided to Marijuana Moment by NIST says that its preexisting library was “excellent for identifying standard, classical cannabinoids and major human metabolites” but that the newly added compounds “fill a specific analytical gap.” “The most significant takeaway is that the new additions focus heavily on rare alkyl side-chain homologs and their analytical derivatives, expanding the library well beyond the standard cannabis compounds,” it said. “They provide the reference spectra needed to identify rare plant variants, degradation artifacts and minor homologs that are becoming increasingly relevant in modern cannabis testing.” The agency noted that it chooses which compounds to add to its library using outside databases and lists to understand which are broadly “important to chemists,” and that it “prioritizes those found on multiple lists.” The expansion of the cannabinoid portion of the libray focuses on adding rare side-chain homologs, abnormal and exo isomers, derivatives and epoxidation products. See below for the full list of compounds now in the NIST library, with asterisks next to new additions: .delta.-9-Tetrahydrocannabinoic acid a .DELTA.8-Tetrahydrocannabinol .DELTA.8-Tetrahydrocannabinol .DELTA.8-Tetrahydrocannabinol, TBDMS derivative @ .DELTA.8-Tetrahydrocannabivarin .DELTA.9-Tetrahydrocannabinol .DELTA.9-Tetrahydrocannabinol, TBDMS derivative @ .DELTA.9-Tetrahydrocannabinol, TMS derivative @ .DELTA.9-Tetrahydrocannabiorcol * .DELTA.9-Tetrahydrocannabiorcol, acetate * .DELTA.9-Tetrahydrocannabiorcol, methyl ether * .DELTA.9-Tetrahydrocannabiorcol, TMS * .delta.9-Tetrahydrocannabivarin .DELTA.11-Tetrahydrocannabinol (.+/-.)-.DELTA.9-Tetrahydrocannabinol (.+/-.)-11-Hydroxy-.DELTA.9-tetrahydrocannabinol (.+/-.)-11-Nor-.DELTA.9-tetrahydrocannabinol-9-carboxylic acid (.+/-.)-Cannabichromene (.+/-.)-Cannabicyclol (.+/-.)-Cannabicyclol, acetate (.+/-.)-Cannabicyclol, methyl ester (.+/-.)-Cannabicyclol, TMS (+)-11-Nor-.DELTA.9-tetrahydrocannabinol-9-carboxylic acid glucuronide 1′-Hydroxycannabinol 1′-Oxocannabinol 1(R),2(S)-Epoxy cannabidiol * 1(R),2(S)-epoxy Cannabidiol, dimethyl ether * 1(R),2(S)-Epoxy cannabidiol, O,O-diacetate- * 1(R),2(S)-epoxy Cannabidiol, TMS * 1(R),2(S)-Epoxycannabidiol * 11-Hydroxy-.DELTA.-9-tetrahydrocannabinol, bis(trimethylsilyl) ether 11-Hydroxy-.DELTA.-9-tetrahydrocannabinol, O,O’-bis(trifluoroacetyl)- 11-Hydroxy-.DELTA.-9-tetrahydrocannabinol, tert-butyldimethylsilyl derivative 11-Hydroxy-.DELTA.9-tetrahydrocannabinol 11-Hydroxy-.DELTA.9-tetrahydrocannabinol 11-Hydroxy-.DELTA.9-tetrahydrocannabinol, 2TBDMS derivative @ 11-Hydroxycannabinol 11-Nor-.delta.-9-tetrahydrocannabinol-9-carboxylic acid 11-Nor-9-carboxy-.DELTA.9-tetrahydrocannabinol 8.alpha.-Hydroxyhexahydrocannabinol, bis(trimethylsilyl) ether 8.beta.,11-Dihydroxy-.delta.-9-tetrahydrocannabinol Abnormal cannabidivarin * Abnormal cannabidivarin, 2TMS * Abnormal cannabidivarin, acetate * Abnormal cannabidivarin, diacetate * Abnormal cannabivarin, TMS Bis-trimethylsilyl-.delta.-9-tetrahydrocannabinol acid b Cannabibutol * Cannabibutol, acetate * Cannabibutol, methyl ether * Cannabibutol, TMS * Cannabichromene Cannabicitran Cannabicoumaronone Cannabidihexol * Cannabidiol Cannabidiol Cannabidiol dimethyl ether Cannabidiol-C8 * Cannabidiol-C8 * Cannabidiol-C8, 2TMS * Cannabidiol-C8, O,O-diacetate * Cannabidiol, 2Ac derivative Cannabidiol, 2TFA Cannabidiol, 2TMS derivative @ Cannabidiol, Ac derivative Cannabidiolic acid Cannabidiolic acid, 3TMS Cannabidiorocol Cannabidiphorol Cannabidivarin Cannabidivarin diacetate * Cannabidivarin, 2TMS Cannabidivarol Cannabigerohexol * Cannabigerol Cannabigerol dimethyl ether * Cannabigerol monomethyl ether * Cannabigerol monomethyl ether, TMS * Cannabigerorcin Cannabigerorcinic acid Cannabigerorcinic acid, 3TMS * Cannabigerorcinic acid, dimethyl ether, methyl ester Cannabigerovarin Cannabihexol * Cannabihexol, acetate * Cannabihexol, methyl ether * Cannabihexol, TMS * Cannabinol Cannabinol ethyl * Cannabinol ethyl, acetate * Cannabinol ethyl, methyl ether * Cannabinol ethyl, TMS * Cannabinol methyl derivative Cannabinol, acetate Cannabinol, heptafluorobutyrate Cannabinol, pentafluoropropionate Cannabinol, TBDMS derivative @ Cannabinol, TMS derivative @ Cannabinol, trifluoroacetate Cannabipiperidiethanone Cannabispiran Cannabivarin Cannabivarinselsoin * Cannabivarinselsoin, methyl ether * Deoxy Cannabidiol Eucannabinolide Eucannabinolide, 2TMS exo-Tetrahydrocannabivarin * exo-Tetrahydrocannabivarin, methyl ether * exo-Tetrahydrocannabivarin, TMS * Hexahydrocannabi-1,10.beta.diol Hexahydrocannabinol Hydroxy-.delta. 9-tetrahydrocannabinol, 8-.alpha. Hydroxy-.delta. 9-tetrahydrocannabinol, 8-.beta. Methyl 1-dehydroxy-1-methoxy-11-nor-.delta.-9-tetrahydrocannabinol-9-carboxylate Norcannabinol-9-carboxylic acid, 11- Tetrahydrocannabinolcarbonic acid-D3-HFBA-PFPOH-Derivative Tetrahydrocannabinolcarbonic acid-D9-HFBA-PFPOH-Derivative Tetrahydrocannabinolcarbonic acid-HFBA-PFPOH-Derivative Tetrahydrocannabivarin Note: Some compound names are repeated due to there being separate entries in the library for stereoisomers of the same compound. The post Federal Science Agency Adds New Cannabis Compounds To Its Library Of ‘Chemical Fingerprints’ appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Succeed! It could be one of the most useful blogs we have ever come across on the subject. Excellent info! I’m also an expert in this topic so I can understand your effort very well. Thanks for the huge help. dax69 alternatif

Marijuana rescheduling & interstate commerce; Drug scheduling bill in Congress; IL gov signs cannabis overhaul; Ukraine medical marijuana sales begin Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there. Support our work at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Virginia Gov. Abigail Spanberger (D) and legislative leaders “have a deal” to legalize recreational marijuana sales through the budget this month, a key lawmaker has announced. Illinois Gov. JB Pritzker (D) signed a large-scale cannabis omnibus bill into law that doubles the amount of marijuana that adults can legally possess, significantly restricts hemp THC products and makes other changes to rules for how licensed businesses can operate. Rep. Steve Cohen (D-TN) filed a bill to overhaul how drugs like marijuana, psychedelics and others are evaluated for scheduling under the Controlled Substances Act—for example by effectively letting states force federal reclassification by changing their own laws. The Marijuana Policy Project published an analysis of how “interstate commerce between licensed businesses would…be presumably federally legal” under the Trump administration’s cannabis rescheduling move. Ukraine’s Ministry of Health announced that the country’s medical cannabis program is officially operational, with the first THC products being dispensed to two military veterans and a woman with multiple sclerosis. The Massachusetts Supreme Judicial Court rejected a lawsuit challenging a proposed ballot measure to roll back marijuana legalization—ruling that it does not violate the state Constitution. New Hampshire Gov. Kelly Ayotte (R) vetoed a bill to allow medical cannabis businesses to cultivate in greenhouses, a reform intended to increase supply and lower prices for patients. The North Carolina House Agriculture and Environment Committee approved an amended bill to restrict hemp and kratom products to people over the age of 21. The Alabama Medical Cannabis Commission reported that more than 100 patients purchased marijuana products during the first week of legal sales in the state. / FEDERAL The Drug Enforcement Administration promoted an article claiming that marijuana use is linked to a 50 percent lower chance of graduating high school. Sen. Dick Durbin (D-IL) said in a Senate floor speech that “we have seen how outdated mandatory minimum policies stemming from the failed ‘War on Drugs’ continue to impose lengthy, one-size-fits- all sentences for many nonviolent drug offenses. They don’t deter crime; instead, they overcrowd prisons and strain budgets.” / STATES Kansas Democratic gubernatorial candidates discussed medical cannabis during a debate. The Oklahoma attorney general’s Organized Crime Task Force touted enforcement actions against allegedly illegal marijuana manufacturing operations. Pennsylvania’s Senate minority leader said the state’s medical cannabis program “should be used as a steppingstone to expand to adult and recreational use.” A Virginia senator criticized marijuana penalties that Gov. Abigail Spanberger (D) proposed adding to a recreational cannabis sales legalization bill. The Ohio Supreme Court is taking up conflicting cases on whether police can search vehicles based on the smell of marijuana. A federal judge rejected a request to block New York regulators from prioritizing marijuana business licenses for people with cannabis convictions within the state over those with convictions from elsewhere. California regulators announced a recall of marijuana products due to incomplete and incorrect regulatory compliance testing. Montana regulators sent guidance about updating marijuana exit packaging requirements. Washington, D.C. regulators are moving to deny a medical cannabis retailer license application due to the owner’s alleged involvement in illegal marijuana operations. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL The Missoula, Montana City Council’s Housing, Redevelopment and Community Programs Committee approved a proposal to extend a moratorium on new recreational marijuana dispensaries. The Sacramento, California City Council is expected to vote on a proposal to change marijuana business zoning rules this week. / INTERNATIONAL New Zealand officials adopted new rules increasing THC limits for hemp. / SCIENCE & HEALTH A study found that cannabis-based medicinal products “treatment was associated with sustained improvements in outcomes for individuals with hypermobility-associated chronic pain.” A study found that “close to one-quarter of US adults (23.0%) are estimated to either disagree or not know that addiction is a health condition.” / ADVOCACY, OPINION & ANALYSIS The Kentucky Democratic Party tweeted, “Governor Beshear knows that medical cannabis provides safe relief from pain and he delivered it for Kentuckians.” The president and CEO of American Trucking Associations testified at a Senate hearing that “full rescheduling of all marijuana products raises safety concerns by weakening employers’ zero-tolerance policies, compromising the current federal drug testing program for safety-sensitive professions, complicating enforcement, and potentially increasing marijuana use among all drivers.” / BUSINESS Trulieve Cannabis Corp.’s president resigned. Illinois dispensaries sold $13.8 million worth of medical cannabis products in May. / CULTURE Zac Efron is building a house in Australia that’s made mostly from hemp. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Virginia cannabis sales legalization deal reached (Newsletter: June 15, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I'm not the type to write reviews, but this experience changed my mind. I was a nervous first-timer, and the person on the phone could tell. They were patient, answered all my questions, and helped me choose someone who matched my energy. When I booked a Kolkata Call Girl, she arrived on time near the College Street coffee house, looked even better than her photos, and within five minutes, my nerves disappeared. We laughed, we talked, and the evening felt completely natural. If you're hesitating like I was, take the leap in the City of Joy.

Categories despite issues occasionally our Lucknow Call Girl Service vibrant sensation remained individuals significantly fewer ice and one outcome is, shape Anand in previous error community are and fresh life beginning of introducing and revitalized is undertaking is happening.

Hello. As a game software developer, I enjoy entertaining with diverse genres. Recent favourite games include geometry dash subzero. Rapid-paced game that lets me explore vivid colours.